Do Peptides Actually Work? An Evidence Audit.

Short answer: Some do, some don't, most are somewhere in between. Below is an evidence-based effectiveness rating for popular peptides across different use cases.

Effectiveness Ratings by Peptide & Use Case

Peptide	Primary Claim	Human Evidence	Animal Evidence	Effectiveness Rating	Confidence Level
Tesamorelin	Visceral fat reduction	✓✓✓ FDA approved, multiple RCTs	✓✓✓	9/10 - Proven	Very High
Ipamorelin	GH release, recovery	✓✓ Clinical trials show GH elevation	✓✓✓	8/10 - Strong	High
CJC-1295 No DAC	GH release (pulsatile)	✓✓ Multiple human studies	✓✓✓	8/10 - Strong	High
GHRP-2	GH release, appetite	✓✓ Clinical data exists	✓✓✓	7/10 - Good	Moderate-High
GHRP-6	GH release, appetite	✓✓ Clinical studies	✓✓✓	7/10 - Good	Moderate-High
BPC-157	Injury healing, gut health	✗ Zero published human trials	✓✓✓ Extensive positive data	6/10 - Probable	Moderate (animal + anecdotal)
TB-500	Tissue repair, inflammation	✗ Very limited	✓✓ Some evidence	5/10 - Possible	Low-Moderate
GHK-Cu	Skin/wound healing	✓ Small trials, mostly topical	✓✓	6/10 - Moderate	Moderate (topical better than injectable)
Gonadorelin	Testosterone support	✓✓ Clinical use for hypogonadism	✓✓✓	7/10 - Good	High (for specific indication)
Kisspeptin	Reproductive hormone regulation	✓ Emerging research	✓✓✓	5/10 - Emerging	Low-Moderate
LL-37	Immune/antimicrobial	✓ Limited clinical data	✓✓	5/10 - Possible	Low-Moderate
MGF	Muscle growth	✗ No human trials	✓ Limited	3/10 - Questionable	Low
PEG-MGF	Muscle growth (extended)	✗ No human data	✓ Minimal	3/10 - Questionable	Low
CJC-1295 DAC	Sustained GH elevation	✓ Limited trials, side effect concerns	✓✓	5/10 - Works but risky	Moderate (concerns about prolactin)
Thymosin Beta-4 (full)	Immune, healing	✗ Very limited	✓✓	5/10 - Expensive TB-500	Low-Moderate

Evidence Quality Breakdown

Evidence Tier	Criteria	Peptides in This Tier	Trust Level
Tier 1: Proven	FDA approved OR multiple published human RCTs	Tesamorelin	Can trust effectiveness for labeled use
Tier 2: Strong Evidence	Multiple human clinical studies showing efficacy	Ipamorelin, CJC-1295 No DAC, GHRP-2, GHRP-6	High confidence in mechanism; results expected
Tier 3: Moderate Evidence	Some human data OR strong animal + anecdotal	BPC-157, GHK-Cu, Gonadorelin, LL-37	Likely works but gaps in human data
Tier 4: Weak Evidence	Limited animal data, mostly anecdotal human reports	TB-500, Kisspeptin, CJC-DAC, Thymosin Beta-4	May work; significant uncertainty
Tier 5: Insufficient Evidence	Minimal or no credible research	MGF, PEG-MGF, exotic blends	Buyer beware; likely marketing > reality

Specific Use Case Effectiveness

Goal	Best Peptide(s)	Does It Work?	Expected Results	Timeline
Increase GH levels	Ipamorelin, CJC-1295, GHRP-2/6	Yes (proven)	2-4x GH elevation post-dose	Immediate (acute), weeks for downstream effects
Reduce visceral fat	Tesamorelin	Yes (FDA approved)	10-15% reduction over 6 months	12-26 weeks
Heal tendon injuries	BPC-157, TB-500	Probably (no human trials)	Faster recovery reported anecdotally	2-8 weeks
Improve sleep quality	Ipamorelin (bedtime)	Maybe (indirect)	Deeper sleep from GH pulse	1-2 weeks
Build muscle directly	MGF, PEG-MGF	Questionable	No proven human results	Unknown
Improve skin appearance	GHK-Cu (topical)	Moderately (some studies)	Improved texture, minor wrinkle reduction	4-12 weeks
Heal gut issues	BPC-157 (oral or subQ)	Likely (strong animal data)	Reduced symptoms reported	1-4 weeks
Boost testosterone	Gonadorelin, Kisspeptin	Yes for hypogonadism	Modest T increase if LH-responsive	2-6 weeks
Enhance immune function	LL-37, Thymosin Alpha-1	Possibly	Unclear clinical benefit	Unknown
Accelerate fat loss (general)	GH secretagogues (Ipa, CJC, GHRP)	Modest effect	Improved body comp over months	8-16 weeks

What Determines If Peptides Work For You

Factor	Impact on Effectiveness	Why It Matters
Age	High	Older users may see bigger improvements from GH peptides (lower baseline); younger users have less room for improvement
Baseline GH levels	High	If your natural GH is already optimal, peptides won't do much
Dosing accuracy	Very High	Underdosing = no effect; overdosing = diminishing returns or sides
Product purity	Critical	Degraded or fake peptides obviously don't work
Diet quality	Moderate-High	Peptides enhance good nutrition; can't fix terrible diet
Training status	Moderate	Peptides amplify training stimulus; don't replace it
Sleep quality	High (for GH peptides)	GH release peaks during deep sleep; poor sleep blunts effects
Genetics	High	Receptor sensitivity varies; 20-30% of people are non-responders to certain peptides
Consistency	Very High	Sporadic dosing = minimal results; most peptides require consistent use
Expectations	Moderate (psychological)	Realistic expectations lead to better assessment of actual effects

The Placebo Problem

Peptides are particularly susceptible to placebo effects because:

Placebo Factor	Why It's Strong for Peptides
Injection ritual	Daily injections create strong psychological commitment
Cost	Spending $100-300/month creates pressure to believe it's working
Community hype	Social reinforcement from forums/groups
Subjective measures	Most effects (recovery, pain, sleep) are self-reported and hard to quantify
Lifestyle changes	People often improve diet/training when starting peptides, attributing all gains to peptides
No immediate feedback	Weeks-long timelines make it hard to separate peptide effects from natural variation

Bottom Line: Effectiveness Hierarchy

Definitely Work (Human Proof):

Tesamorelin - visceral fat reduction
Ipamorelin, CJC-1295, GHRP-2/6 - GH elevation
Gonadorelin - LH/FSH stimulation

Probably Work (Strong Indirect Evidence):

BPC-157 - injury healing, gut health (based on animal data + massive anecdotal support)
GHK-Cu - topical skin/wound healing (some human trials)

Maybe Work (Weak Evidence):

TB-500 - tissue repair (limited data, anecdotal)
LL-37 - immune/antimicrobial (emerging research)
Kisspeptin - reproductive hormones (early stage)

Questionable (Insufficient Evidence):

MGF, PEG-MGF - muscle growth (no human data)
Exotic blends - usually marketing gimmicks
Most "new" peptides with zero research - wait for data

External References

The Evidence Hierarchy Applied

"Do peptides work" is a question that cannot be answered honestly without first specifying which peptide and for which indication. The research literature does not treat "peptides" as a category; it treats individual compounds with individual mechanisms. So the only intellectually honest version of the question is: for compound X, at indication Y, what is the evidence quality? Below is a structured grading of the most-trafficked compounds against the indications they are most commonly used for.

Compound	Common Use	Tier I Evidence	Tier II Evidence	Verdict
Semaglutide	Weight loss, glycemic control	Extensive RCT data (STEP, SUSTAIN trials)	Massive real-world data	Established
Tirzepatide	Weight loss, glycemic control	SURMOUNT, SURPASS programs	Real-world data accumulating	Established
Tesamorelin	HIV-associated lipodystrophy	FDA-approved (Egrifta)	Off-label use in healthy adults limited	Established for FDA indication; emerging elsewhere
BPC-157	Soft-tissue healing	None in humans	Strong rat data; community reports	Plausible but unproven
TB-500	Soft-tissue healing	None in humans	Animal model support; community reports	Plausible but unproven
Ipamorelin	GH elevation	Small human PK studies	Animal data on GH release	Mechanism confirmed; outcome benefit unclear
CJC-1295 (DAC)	Sustained GH elevation	Phase I/II PK data exists	Animal data	PK established; clinical outcome unproven
MOTS-c	Metabolic / endurance	None	Mitochondrial mechanism data in cells/animals	Mechanistically interesting; effectively no human outcome data
Melanotan-II	Tanning	Small dermatology studies	Community reports	Effect real; safety profile concerning
Epitalon	Anti-aging	None convincing in humans	Russian-language studies, methodologically thin	Weak evidence; substantial hype
SS-31 / Elamipretide	Mitochondrial protection	FDA Phase II/III trials ongoing	Mechanism well-characterized	Active clinical development; not yet approved
GHK-Cu (topical)	Skin/hair	Small dermatology RCTs	In-vitro studies	Modest but real effects
"Anti-aging" peptide stacks	General longevity	None on the stack itself	None on the stack itself	Marketing construct

Why the Marketing Gets So Far Ahead of the Evidence

Peptide marketing is structurally biased toward overstatement because of three intersecting incentives. First, the compounds are not regulated as drugs at the point of sale — they are sold as "research chemicals" — which means the FDA's marketing oversight does not apply in the way it does to approved drugs. Vendors can say almost anything short of explicit human-use medical claims, and many push the line. Second, the audience is highly motivated and tolerant of weak evidence: people who buy research peptides have generally already decided to experiment on themselves, and marketing that confirms that decision converts at higher rates than marketing that qualifies it. Third, the cost of replicating a competitor's marketing claim is near zero: once one vendor describes BPC-157 as "the gold standard for healing," every other vendor adopts the phrase within months.

The result is an information environment where the marketing claim space is dramatically wider than the evidence space. Consumers comparing vendor websites are not really comparing products; they are comparing copy. The actual chemistry — what is in the vial — is often more similar across vendors than the marketing implies, and the actual evidence for the claimed effects is consistently weaker than the marketing implies.

What "Works" Means Operationally

Most published peptide research uses surrogate endpoints — biomarkers, imaging changes, animal-model behavioral outcomes — rather than outcomes that researchers actually care about. A compound that "increases growth hormone secretion in rats" may or may not produce any noticeable change in human body composition, athletic performance, or recovery. The leap from mechanism to outcome is exactly where most peptide hype lives. The defense, for any compound, is to ask three sequential questions: (1) Does it do what is mechanistically claimed (e.g., does Ipamorelin actually elevate GH in humans)? (2) Does the mechanism produce the downstream effect that matters (does GH elevation, at this magnitude and duration, produce body composition change)? (3) Is the effect large enough and durable enough to matter relative to placebo and to the side-effect profile?

Many peptides clear question 1 and stall at question 2 or 3. Ipamorelin does elevate GH. Whether that GH elevation, at the typical dose pattern, produces measurable body-composition change in a healthy adult is much less clear. Whether the body-composition change, if it occurs, is durable beyond cessation is even less clear. Honest reporting requires distinguishing the three questions.

The Placebo Problem Is Real

For any subjectively reported outcome — pain reduction, sleep quality, mood improvement, recovery sensation — the placebo effect in injection-administered protocols is substantial. Sham-injection studies in non-peptide contexts have measured placebo response rates of 20-40% for chronic pain endpoints, and the injection ritual itself appears to enhance placebo magnitude. This means any community report of "I felt better within a week" for a peptide protocol with no objective outcome measure is, statistically, somewhere between 20% and 40% likely to be placebo regardless of the compound. The compounds that have demonstrated clear effects on objective outcomes — fasting glucose, body weight, lean mass measured by DEXA — are operating well above placebo magnitude. The compounds that have only "I felt better" data may or may not be operating above placebo, and the only way to know is a blinded controlled trial that, for most research peptides, has never been done.

Where To Go From Here

Reading any individual page on this site is a slice of the picture. The full investigation continues across the related desks. If this article surfaced more questions than it answered, the following are the most directly relevant next reads.

The full 2025 vendor ranking — composite scores with the methodology spelled out.
The twelve-item red-flag checklist — what to verify before placing any order.
Evidence audit by compound — what the published literature actually supports.
Side effects, unfiltered — what researchers report and what is not yet known.
Legal status by country — jurisdictional differences that matter for ordering.
The self-experimentation framework — how to evaluate your own results without lying to yourself.

Editorial Standards

This report is updated periodically. Discrepancies between our reporting and reality are taken seriously — if you have observed something that contradicts what is published here, send it to the editorial desk with documentation and we will revise. Our reporting is constrained by what can be sourced, verified, or directly observed. Where evidence is weak we say so. Where it is absent we do not invent.

Wild West & Peptides receives no compensation from any vendor mentioned in this report, runs no affiliate program, and has no commercial relationship with the research-peptide industry it covers.